Get the Stockscreener App
1.64
3.53%
-0.06
Pre-market:
1.64
Longeveron Inc Stock (LGVN) Latest News
Laromestrocel shows promise in Alzheimer’s trial By Investing.com - Investing.com Australia
Longeveron® Announces Nature Medicine Publication Of Results Of Phase 2A Clinical Trial Evaluating Laromestrocel (Lomecel-B(TM)) In Alzheimer'S Disease - Marketscreener.com
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease - The Manila Times
Longeveron announces publication of results of Phase 2a trial of Lomecel-B - TipRanks
Longeveron Inc. Reports Positive Phase 2a Results for Laromestrocel (Lomecel-B™) in Mild Alzheimer’s Disease Treatment - Nasdaq
Game-Changing Alzheimer's Treatment: Longeveron's Drug Delivers Cognitive Improvements in Nature Study - StockTitan
Q1 Earnings Estimate for Longeveron Issued By Roth Capital - Defense World
Q1 Earnings Forecast for Longeveron Issued By HC Wainwright - Defense World
Q1 Earnings Forecast for Longeveron Issued By Roth Capital - Defense World
FY2025 EPS Estimates for Longeveron Reduced by Analyst - Defense World
Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Call Transcript - MSN
Longeveron® to Present at the 37th Annual Roth Conference - The Manila Times
How Longeveron's Upcoming Roth Conference Appearance Could Spotlight Its Cellular Therapy Pipeline - StockTitan
Longeveron Inc. Reports Strong 2024 Financial Growth - TipRanks
Longeveron (NASDAQ:LGVN) Receives Buy Rating from HC Wainwright - Defense World
Longeveron Inc. Earnings Call: Growth and Challenges - TipRanks
Longeveron Inc (NASDAQ: LGVN) Declines -0.65%: This $22.55 million Stock Could Go Down -557.89% - Stocks Register
LGVN To Complete ELPIS II Enrollment By Q2, Time To Keep An Eye On NXGL, What's The Buzz At ACON? - RTTNews
Earnings call transcript: Longeveron Q4 2024 sees revenue surge, stock gains - Investing.com Canada
Longeveron Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Can Longeveron's 237% Revenue Surge and Advanced Clinical Trial Transform Pediatric Heart Treatment? - StockTitan
LONGEVERON Earnings Preview: Recent $LGVN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Longeveron (LGVN) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Longeveron® Announces World Health Organization Approval of “laro - The National Law Review
LGVNRLongeveron Latest Stock News & Market Updates - StockTitan
Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025 - The Manila Times
Longeveron Inc. to Announce Full-Year 2024 Financial Results and Company Update on February 28, 2025 - Nasdaq
Longeveron Cellular Therapy Granted International Non-Proprietary Name -February 18, 2025 at 10:33 am EST - Marketscreener.com
Longeveron’s Lomecel receives WHO non-proprietary name approval as laromestroce - TipRanks
Longeveron® Announces World Health Organization Approval of - GlobeNewswire
Breakthrough Alzheimer's Treatment Gets Official WHO RecognitionMajor Milestone for Rare Disease Therapy - StockTitan
Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025 - Marketscreener.com
Biotech Breakthrough: Longeveron Reveals Latest Regenerative Medicine Advances at Major Conference - StockTitan
Longeveron announces board member resignation - MSN
Longeveron announces board member resignation By Investing.com - Investing.com South Africa
Longeveron Board Member Neil Hare Resigns - TipRanks
Geode Capital Management LLC Acquires 97,953 Shares of Longeveron Inc. (NASDAQ:LGVN) - Defense World
State Street Corp Takes Position in Longeveron Inc. (NASDAQ:LGVN) - Defense World
Longeveron (NASDAQ:LGVN) Stock Price Up 1.1% – Here’s What Happened - Defense World
Longeveron to Present at Biotech Showcase 2025 - The Manila Times
Longeveron CEO to Present at Biotech Showcase 2025: Spotlight on Regenerative Medicine Breakthroughs - StockTitan
Longeveron (NASDAQ:LGVN) Earns Buy Rating from Analysts at Roth Mkm - Defense World
Longeveron (NASDAQ:LGVN) Upgraded at Roth Capital - Defense World
Longeveron initiated with a Buy at Roth MKM - Yahoo Finance
Roth MKM Initiates Coverage of Longeveron (LGVN) with Buy Recommendation - MSN
Longeveron director Baluch Khoso sells $2,588 in stock By Investing.com - Investing.com Canada
Longeveron director Baluch Khoso sells $2,588 in stock - Investing.com
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):